LUND, Sweden, June 7, 2021 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announces that
the scientific journal Expert Opinion on Biological Therapy has
published an article by scientists at Alligator Bioscience,
reviewing the field of CD40 agonistic antibodies. The article
provides an overview of the CD40 agonistic antibodies in clinical
development and the current challenges and opportunities for this
important class of immuno-oncology drugs.
Title: Rationale and clinical development of CD40
agonistic antibodies for cancer immunotherapy
Journal: Expert Opinion on Biological
Therapy
Authors: Karin Enell Smith et
al
The full article is available online and can be found at:
https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1934446
"We're very pleased to have this peer-reviewed article
prepared by Alligator's scientists published. It highlights the
promising role of CD40 agonists in immuno-oncology and explains how
Alligator's CD40 agonist, mitazalimab, has best in class
potential," said Søren Bregenholt, CEO of Alligator
Bioscience. "We're now looking forward to initiating the
OPTIMIZE-1 Phase II study designed to assess the clinical efficacy
of mitazalimab combined with chemotherapy in patients with
metastatic pancreatic cancer."
Mitazalimab is an agonistic – or stimulatory – antibody that
targets CD40, a receptor on dendritic cells, which are the cells
that instruct T cells to kill cancer cells. Mitazalimab activates
CD40 enabling dendritic cells to effectively stimulate the immune
system directing T cells to selectively attack the tumor. This
addresses one of the key mechanistic needs in immuno-oncology and
highlights the potential of CD40 as a target to treat patients with
metastatic cancer. Mitazalimab's favorable efficacy-safety profile
demonstrated in previous phase I studies, makes it ideal for
combination with standard of care treatments such a chemotherapy,
check-point inhibitors or cancer vaccines.
For further information, please contact:
Søren Bregenholt, CEO
E-mail: sbr@alligatorbioscience.com
Phone: +46 46-540 82 00
The information was submitted for publication, through the
agency of the contact person set out above, at 08:00 a.m. CEST on June 7,
2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets:
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc. In
addition, the company has developed a novel concept for more
patient-specific immunotherapy: Neo-X-PRIME. Alligator's shares are
listed on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden. For more
information, please visit www.alligatorbioscience.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/article-on-cd40-agonistic-antibodies-published-in-expert-opinion-on-biological-therapy,c3361875
The following files are available for download:
|
https://mb.cision.com/Main/12681/3361875/1428306.pdf
|
Release
|